Partha Sardar1, Saurav Chatterjee2, Jay Giri3, Amartya Kundu4, Anwar Tandar5, Parijat Sen6, Ramez Nairooz7, Jessica Huston5, John J Ryan5, Riyaz Bashir8, Sahil A Parikh9, Christopher J White10, Philip M Meyers11, Debabrata Mukherjee12, Jennifer J Majersik13, William A Gray14. 1. Division of Cardiovascular Medicine, University of Utah Health Science Center, University of Utah, 30 North 1900 East, Salt Lake City, UT 84132, USA parthasardarmd@gmail.com. 2. St Luke's-Roosevelt Hospital of the Mount Sinai Health System, New York, NY, USA. 3. Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 4. University of Massachusetts Medical School, Worcester, MA, USA. 5. Division of Cardiovascular Medicine, University of Utah Health Science Center, University of Utah, 30 North 1900 East, Salt Lake City, UT 84132, USA. 6. Saint Michael's Medical Center, Newark, NJ, USA. 7. University of Arkansas for Medical Sciences, Little Rock, AR, USA. 8. Temple University School of Medicine, Philadelphia, PA, USA. 9. University Hospitals Case Medical Center, Cleveland, OH, USA. 10. Ochsner Clinical School, Ochsner Medical Center, New Orleans, LA, USA. 11. Radiology and Neurological Surgery, Columbia University Medical Center, New York, NY, USA. 12. Texas Tech University Health Sciences Center, El Paso, TX, USA. 13. Division of Vascular Neurology, University of Utah, Salt Lake City, UT, USA. 14. Center for Interventional Vascular Therapy, Columbia University Medical Center, New York, NY, USA.
Abstract
AIMS: Evidence from randomized controlled trials (RCTs) evaluating possible benefits of endovascular therapy (EVT) for acute ischaemic stroke has shown conflicting results. The purpose of this meta-analysis was to systematically examine clinical outcomes in RCTs comparing the use of intravenous (IV) fibrinolysis alone to IV fibrinolysis plus EVT, for the treatment of acute ischaemic stroke. METHODS AND RESULTS: We selected English language RCTs, comparing EVT plus IV tissue-type plasminogen activator (tPA) (if eligible) with IV tPA alone in eligible patients for the treatment of acute ischaemic stroke. The primary endpoint was good functional outcome [modified Rankin Scale (mRS) of 0-2]. Other major endpoints of interest were all-cause mortality and symptomatic intracerebral haemorrhage (sICH). The meta-analysis included 8 RCTs that randomized 2423 patients with large-vessel, anterior-circulation stroke. EVT significantly improved the rate of functional independence (90-day mRS of 0-2) when compared with IV fibrinolysis [odds ratio (OR) 1.73, 95% confidence interval (CI) 1.18-2.53, number needed to treat (NNT) = 9.3]. The all-cause mortality was lower with EVT compared with the control group; however, the result did not reach statistical significance (OR 0.89, 95% CI 0.68-1.15). The rate of sICH was not higher with EVT (OR 1.07, 95% CI 0.73-1.56). Analyses from only the recent trials (reported in 2014-15) showed further benefit (OR of mRS 0-2: 2.42, 95% CI 1.91-3.08, NNT = 5) with similar safety results. CONCLUSION: In centres with advanced systems of stroke care, EVT significantly improved functional outcomes (without compromising safety) in patients with acute ischaemic stroke due to anterior circulation, large artery occlusion, compared with standard therapy. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Evidence from randomized controlled trials (RCTs) evaluating possible benefits of endovascular therapy (EVT) for acute ischaemic stroke has shown conflicting results. The purpose of this meta-analysis was to systematically examine clinical outcomes in RCTs comparing the use of intravenous (IV) fibrinolysis alone to IV fibrinolysis plus EVT, for the treatment of acute ischaemic stroke. METHODS AND RESULTS: We selected English language RCTs, comparing EVT plus IV tissue-type plasminogen activator (tPA) (if eligible) with IV tPA alone in eligible patients for the treatment of acute ischaemic stroke. The primary endpoint was good functional outcome [modified Rankin Scale (mRS) of 0-2]. Other major endpoints of interest were all-cause mortality and symptomatic intracerebral haemorrhage (sICH). The meta-analysis included 8 RCTs that randomized 2423 patients with large-vessel, anterior-circulation stroke. EVT significantly improved the rate of functional independence (90-day mRS of 0-2) when compared with IV fibrinolysis [odds ratio (OR) 1.73, 95% confidence interval (CI) 1.18-2.53, number needed to treat (NNT) = 9.3]. The all-cause mortality was lower with EVT compared with the control group; however, the result did not reach statistical significance (OR 0.89, 95% CI 0.68-1.15). The rate of sICH was not higher with EVT (OR 1.07, 95% CI 0.73-1.56). Analyses from only the recent trials (reported in 2014-15) showed further benefit (OR of mRS 0-2: 2.42, 95% CI 1.91-3.08, NNT = 5) with similar safety results. CONCLUSION: In centres with advanced systems of stroke care, EVT significantly improved functional outcomes (without compromising safety) in patients with acute ischaemic stroke due to anterior circulation, large artery occlusion, compared with standard therapy. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Chad K Bush; Dayaamayi Kurimella; Lee J S Cross; Katherine R Conner; Sheryl Martin-Schild; Jiang He; Changwei Li; Jing Chen; Tanika Kelly Journal: PLoS One Date: 2016-01-25 Impact factor: 3.240
Authors: Anna Lambrinos; Alexis K Schaink; Irfan Dhalla; Timo Krings; Leanne K Casaubon; Nancy Sikich; Cheemun Lum; Aditya Bharatha; Vitor Mendes Pereira; Grant Stotts; Gustavo Saposnik; Linda Kelloway; Xuanqian Xie; Michael D Hill Journal: Can J Neurol Sci Date: 2016-04-13 Impact factor: 2.104
Authors: Fahad Alqahtani; Chalak O Berzingi; Sami Aljohani; Mohamed Al Hajji; Anas Diab; Muhammad Alvi; Khaled Boobes; Mohamad Alkhouli Journal: J Am Heart Assoc Date: 2018-06-15 Impact factor: 5.501